ARTICLE | Clinical News
Telotristat etiprate: Phase III data
December 7, 2015 8:00 AM UTC
Top-line data from the double-blind, international Phase III TELECAST trial in 76 cancer patients with metastatic neuroendocrine tumors and carcinoid syndrome showed that thrice-daily 250 and 500 mg o...